2024 Q3 Report: Global Trends in Biopharma Transactions Each quarter, Locust Walk’s deal team compiles key statistics and trends on […]
Podcast: Play in new window | Download (Duration: 26:21 — 60.3MB)
Subscribe: Apple Podcasts | Spotify | RSS
On this episode of Biotalk, Locust Walk’s Andy Meyerson welcomes Dr. Lindsay Rosenwald, Chairman, President and Chief Executive Officer of Fortress Biotech, a company
During this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our Q2 2024 Report: Global Trends in Biopharma Transactions Report. Each quarter,
2024 Q2 Report: Global Trends in Biopharma Transactions Each quarter, Locust Walk’s deal team compiles key statistics and trends on
LOCUST WALK NEWS CytoReason secures $80M from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific to scale its AI disease models
LOCUST WALK NEWS Locust Walk Acquisition Corp. Announces Pricing of Upsized $153,000,000 Initial Public Offering PHILADELPHIA and BOSTON, Jan. 7,
LOCUST WALK NEWS Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib Ascentage Pharma
Biopharma’s COVID Capital Comeback What a difference a few months can make – especially during a pandemic. Heading into 2020,
Align Summit 2024 Align Summit – April 25, 2024 Locust Walk proudly partnered with MassBio and McKinsey & Co. for
Loucst Walk RNA Innovation Conference in partnership with Dr. Frank Slack, Director of the Harvard Medical School Initiative for RNA